Allogene’s $110M offering; Apellis refinances

Plus, news about FogPharma, Artbio, Enveric, MindBio and Allozymes:

Allogene taps investors for $110M: The biotech priced a common stock offering that included mutual funds, institutional investors and healthcare specialists. Some board members and executives also took part in the financing. The Bay Area biotech now has rights in the EU and UK for the allogeneic cell therapy called cemacabtagene ansegedleucel. — Kyle LaHucik

Apellis refinances: The commercial-stage biotech received about $375 million in a credit facility from investment firm Sixth Street. About $326 million went to buy out a development liability with SFJ Pharmaceuticals, and the net proceeds were about $32 million. — Kyle LaHucik

FogPharma teams up with Artbio: The biotechs plan to co-develop 212Pb alpha radioligand therapies and will “contribute equally” across R&D and commercialization. No financials were disclosed. Both startups…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks